ArticleCancer medicine2023

Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer.

Takuya Tsujino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.